Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer

Lin,Wumei; Li,Zhigang

doi:10.3892/ol.2017.6094

Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer

Authors:
- Wumei Lin
- Zhigang Li
View Affiliations

Affiliations: Department of Gynecology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China
Published online on: April 25, 2017 https://doi.org/10.3892/ol.2017.6094
Pages: 4897-4904

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the sixth and eighth leading cause of cancer mortality among women in developed and developing countries, respectively. Medical therapy is the main method for the treatment of OC. However, drug toxicity and the marked side effects of chemotherapy limit the usage and therapeutic results of the treatments. Therefore, the identification of multi‑target agents with few side effects and high effectiveness is required. Traditional Chinese medicine has been used clinically to treat various types of cancer for thousands of years and is considered to possess multiple components and agents, which exert efficient therapeutic functions with few side effects. Although blueberries have previously been used to treat various types of cancer, the effect on OC and precise molecular mechanism of function of the fruit remains unknown. Cyclooxygenase (COX)‑1 and COX‑2 have been reported to be the biomarkers of OC. Blueberries may affect the progression of OC by affecting COX levels. To investigate the issue, COX‑1 and COX‑2 were overexpressed or silenced in ovarian cancer SKOV3 cells. The effect of blueberries on SKOV3 cell viability was determined by an MTT assay. Furthermore, a mouse model for OC was established. The results indicated that blueberries inhibited the proliferation of OC cells by downregulating the levels of COX‑1 and COX‑2. Blueberry (400 mg daily) consumption reduced tumor size significantly in mice with OC compared with the control without blueberry treatment (P<0.05). The results suggest that blueberries should be used to develop a potential non‑pharmaceutical therapy for OC.

View Figures

View References

1	Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB and Wenzel L: Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 106:pii: dju1282014. View Article : Google Scholar
2	Chen CH, Chiu LH, Chan C and Liu WM: Management of ovarian cancer in 14th gestational week of pregnancy by robotic approach with preservation of the fetus. Gynecol Obstet Invest. 80:139–144. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yang XJ, Zheng FY, Xu YS and Ou RY: Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: A case study and review of the literature. J Ovarian Res. 7:202014. View Article : Google Scholar : PubMed/NCBI
4	Shim SH, Kim DY, Seo MJ, Lee SW, Park JY, Lee JJ, Kim JH, Kim YM, Kim YT and Nam JH: Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer. Int J Gynecol Cancer. 23:1383–1392. 2013. View Article : Google Scholar : PubMed/NCBI
5	Peng X, Wang P, Li S, Zhang G and Hu S: Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 13:502015. View Article : Google Scholar : PubMed/NCBI
6	Mir MC, Stephenson AJ, Grubb RL III, Black A, Kibel AS and Izmirlian G: Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 22:2241–2249. 2013. View Article : Google Scholar : PubMed/NCBI
7	Nagano H, Muraoka M and Takagi K: Recurrent ovarian cancer with multiple lymph nodes metastases successfully treated with lymphadenectomy as secondary cytoreductive surgery: A case report. Int J Surg Case Rep. 5:412–415. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bacalbasa N and Popescu I: Ovarian cancer liver metastases-should we apply the principle of optimal cytoreduction to the liver? A review. Hepatogastroenterology. 62:355–357. 2015.PubMed/NCBI
9	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
10	Frampton JE: Olaparib: A review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 29:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
11	Ledermann J, Harter P and Gourley C: Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 16:e1582015.PubMed/NCBI
12	Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, Meng Y and Han W: Low dose decitabine combined with taxol and platinum chemotherapy to treat refractory/recurrent ovarian cancer: An open-label, single-arm, Phase I/II study. Curr Protein Pept Sci. 16:329–336. 2015. View Article : Google Scholar : PubMed/NCBI
13	McGrail DJ, Khambhati NN, Qi MX, Patel KS, Ravikumar N, Brandenburg CP and Dawson MR: Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner. Sci Rep. 5:95292015. View Article : Google Scholar : PubMed/NCBI
14	Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, et al: A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 8:e615202013. View Article : Google Scholar : PubMed/NCBI
15	McNeil EM, Ritchie AM and Melton DW: The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment. DNA Repair (Amst). 12:1000–1006. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, de Vos F, Pattyn P, Peeters M, Remon JP and Vervaet C: In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. Ann Surg Oncol. 17:2510–2517. 2010. View Article : Google Scholar : PubMed/NCBI
17	Arany I, Clark JS, Reed D, Szabo I, Ember I and Juncos LA: The role of p66shc in taxol- and dichloroacetic acid-dependent renal toxicity. Anticancer Res. 33:3119–3122. 2013.PubMed/NCBI
18	Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT and Rubenstein EB: Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer. 13:219–227. 2005. View Article : Google Scholar : PubMed/NCBI
19	Faria A, Pestana D, Teixeira D, de Freitas V, Mateus N and Calhau C: Blueberry anthocyanins and pyruvic acid adducts: Anticancer properties in breast cancer cell lines. Phytother Res. 24:1862–1869. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zu XY, Zhang ZY, Zhang XW, Yoshioka M, Yang YN and Li J: Anthocyanins extracted from Chinese blueberry (Vaccinium uliginosum L.) and its anticancer effects on DLD-1 and COLO205 cells. Chin Med J (Engl). 123:2714–2719. 2010.PubMed/NCBI
21	Kanaya N, Adams L, Takasaki A and Chen S: Whole blueberry powder inhibits metastasis of triple negative breast cancer in a xenograft mouse model through modulation of inflammatory cytokines. Nutr Cancer. 66:242–248. 2014. View Article : Google Scholar : PubMed/NCBI
22	Jeyabalan J, Aqil F, Munagala R, Annamalai L, Vadhanam MV and Gupta RC: Chemopreventive and therapeutic activity of dietary blueberry against estrogen-mediated breast cancer. J Agric Food Chem. 62:3963–3971. 2014. View Article : Google Scholar : PubMed/NCBI
23	Thuresson ED, Lakkides KM and Smith WL: PGG2, 11R-HPETE and 15R/S-HPETE are formed from different conformers of arachidonic acid in the prostaglandin endoperoxide H synthase-1 cyclooxygenase site. Adv Exp Med Biol. 507:67–72. 2002. View Article : Google Scholar : PubMed/NCBI
24	Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, et al: Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 6:21353–21368. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lin Y, Cui M, Xu T, Yu W and Zhang L: Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells. Mol Med Rep. 9:2499–2504. 2014.PubMed/NCBI
26	Hui X, Chen H, Zhang S, Ma X, Wang X and Huang B: Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 311:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Yang WL, Roland IH, Godwin AK and Xu XX: Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene. 24:7991–8002. 2005. View Article : Google Scholar : PubMed/NCBI
29	Montales MT, Rahal OM, Kang J, Rogers TJ, Prior RL, Wu X and Simmen RC: Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis. 33:652–660. 2012. View Article : Google Scholar : PubMed/NCBI
30	Esposito D, Chen A, Grace MH, Komarnytsky S and Lila MA: Inhibitory effects of wild blueberry anthocyanins and other flavonoids on biomarkers of acute and chronic inflammation in vitro. J Agric Food Chem. 62:7022–7028. 2014. View Article : Google Scholar : PubMed/NCBI
31	Paulis G, Cavallini G, Giorgio GD, Quattrocchi S, Brancato T and Alvaro R: Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm Allergy Drug Targets. 12:403–409. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ge I, Rudolph A, Shivappa N, Flesch-Janys D, Hébert JR and Chang-Claude J: Dietary inflammation potential and postmenopausal breast cancer risk in a German case-control study. Breast. 24:491–496. 2015. View Article : Google Scholar : PubMed/NCBI
33	Khachatryan N and Kempen JH: Immunosuppressive therapy and cancer risk in ocular inflammation patients: Fresh evidence and more questions. Ophthalmology. 122:219–221. 2015. View Article : Google Scholar : PubMed/NCBI
34	Magnowska M, Zaborowski M, Surowiak P, Nowak-Markwitz E, Zabel M and Spaczyński M: COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis. Ginekol Pol. 85:335–341. 2014. View Article : Google Scholar : PubMed/NCBI